Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one

An immediate-release pharmaceutical composition comprising:

• a core composition comprising
• a solid dispersion comprising
• (i) at least one active agent chosen from 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one (Compound 1), pharmaceutically acceptable salts thereof, and solvates thereof;
• and
• (ii) at least one matrix polymer, wherein one of said at least one matrix polymers is copovidone;
• and
• wherein the total concentration of Compound 1 in the core composition is in the range of from 10% by weight to 40% by weight;
• wherein the weight ratio of Compound 1 to copovidone in the core composition is in the range of from 1:1 to 1:9.

An immediate-release pharmaceutical composition comprising:

• a core composition comprising
• a solid dispersion comprising 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one (Compound 1) and copovidone;
• wherein the total concentration of Compound 1 in the core composition is 25% by weight;
• and
• wherein the weight ratio of Compound 1 to copovidone in the core composition is 1:2.3.